Compare · ALNY vs IONS
ALNY vs IONS
Side-by-side comparison of Alnylam Pharmaceuticals Inc. (ALNY) and Ionis Pharmaceuticals Inc. (IONS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALNY and IONS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ALNY is the larger of the two at $37.13B, about 3.0x IONS ($12.25B).
- Over the past year, ALNY is down 10.2% and IONS is up 98.1% - IONS leads by 108.3 points.
- IONS has been more active in the news (13 items in the past 4 weeks vs 8 for ALNY).
- Both have 25 recent analyst ratings on file.
- Company
- Alnylam Pharmaceuticals Inc.
- Ionis Pharmaceuticals Inc.
- Price
- $278.14-1.66%
- $74.15-0.12%
- Market cap
- $37.13B
- $12.25B
- 1M return
- -5.57%
- +0.45%
- 1Y return
- -10.18%
- +98.10%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2004
- News (4w)
- 8
- 13
- Recent ratings
- 25
- 25
Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Latest ALNY
- Alnylam to Host Tenth "RNAi Roundtable" Webcast Series
- Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
- Director Pyott David E I sold $1,145,853 worth of shares (3,830 units at $299.18) as part of a pre-agreed trading plan and converted options into 3,830 shares (SEC Form 4)
- SEC Form 4 filed by Director Cravatt Benjamin
- SEC Form 3 filed by new insider Cravatt Benjamin
- SEC Form 144 filed by Alnylam Pharmaceuticals Inc.
- Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum
- Alnylam Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Sigal Charles Elliott was granted 671 shares, increasing direct ownership by 87% to 1,446 units (SEC Form 4)
- Director Schulman Amy W was granted 838 shares, increasing direct ownership by 4% to 24,049 units (SEC Form 4)
Latest IONS
- EVP, Chief Development Officer Kordasiewicz Holly B. exercised 60,846 shares at a strike of $53.97 and sold $4,466,428 worth of shares (60,846 units at $73.41) as part of a pre-agreed trading plan (SEC Form 4)
- Director Berthelsen Spencer R exercised 8,000 shares at a strike of $24.42 and sold $587,920 worth of shares (8,000 units at $73.49) as part of a pre-agreed trading plan (SEC Form 4)
- Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 4 filed by Director Reikes Peter N
- SEC Form 4 filed by Director Hantson Ludwig
- SEC Form 3 filed by new insider Reikes Peter N
- SEC Form 3 filed by new insider Hantson Ludwig
- Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
- Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses